|
Market Closed -
Other stock markets
|
After hours 19:57:23 | |||
| 13.50 EUR | +0.97% |
|
13.53 | +0.22% |
| 01-08 | EVONIK : Barclays remains Neutral | ZD |
| 01-08 | Berenberg Cuts Evonik Industries to Sell on Product Pricing Challenges | MT |
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 12.2B | 14.96B | 18.49B | 15.27B | 15.16B | |||||
Total Revenues | 12.2B | 14.96B | 18.49B | 15.27B | 15.16B | |||||
Cost of Goods Sold, Total | 8.83B | 10.89B | 14.14B | 11.88B | 11.25B | |||||
Gross Profit | 3.37B | 4.07B | 4.35B | 3.39B | 3.91B | |||||
Selling General & Admin Expenses, Total | 2B | 2.25B | 2.57B | 2.32B | 2.62B | |||||
R&D Expenses | 433M | 464M | 460M | 433M | 447M | |||||
Other Operating Expenses | 38M | 82M | -88M | 36M | 4M | |||||
Other Operating Expenses, Total | 2.47B | 2.8B | 2.94B | 2.78B | 3.08B | |||||
Operating Income | 895M | 1.27B | 1.41B | 606M | 834M | |||||
Interest Expense, Total | -171M | -129M | -122M | -244M | -212M | |||||
Interest And Investment Income | 48M | 64M | 144M | 117M | 71M | |||||
Net Interest Expenses | -123M | -65M | 22M | -127M | -141M | |||||
Income (Loss) On Equity Invest. | 15M | 8M | 12M | 10M | 21M | |||||
Currency Exchange Gains (Loss) | -21M | -16M | -45M | -110M | -52M | |||||
Other Non Operating Income (Expenses) | -7M | -19M | -22M | 38M | 14M | |||||
EBT, Excl. Unusual Items | 759M | 1.18B | 1.38B | 417M | 676M | |||||
Restructuring Charges | -15M | -20M | -115M | -64M | -177M | |||||
Merger & Related Restructuring Charges | -28M | - | - | -239M | -24M | |||||
Gain (Loss) On Sale Of Investments | - | -22M | - | 12M | 2M | |||||
Gain (Loss) On Sale Of Assets | -12M | 0 | 43M | -14M | -24M | |||||
Asset Writedown | -21M | -50M | -380M | - | - | |||||
Other Unusual Items | 1M | - | - | -463M | -19M | |||||
EBT, Incl. Unusual Items | 684M | 1.08B | 923M | -351M | 434M | |||||
Income Tax Expense | 181M | 316M | 369M | 101M | 194M | |||||
Earnings From Continuing Operations | 503M | 769M | 554M | -452M | 240M | |||||
Earnings Of Discontinued Operations | -24M | -2M | 1M | - | - | |||||
Net Income to Company | 479M | 767M | 555M | -452M | 240M | |||||
Minority Interest | -14M | -21M | -15M | -13M | -18M | |||||
Net Income - (IS) | 465M | 746M | 540M | -465M | 222M | |||||
Net Income to Common Incl Extra Items | 465M | 746M | 540M | -465M | 222M | |||||
Net Income to Common Excl. Extra Items | 489M | 748M | 539M | -465M | 222M | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 1 | 1.6 | 1.16 | -1 | 0.48 | |||||
Basic EPS - Continuing Operations | 1.05 | 1.61 | 1.16 | -1 | 0.48 | |||||
Basic Weighted Average Shares Outstanding | 466M | 466M | 466M | 466M | 466M | |||||
Net EPS - Diluted | 1 | 1.6 | 1.16 | -1 | 0.48 | |||||
Diluted EPS - Continuing Operations | 1.05 | 1.61 | 1.16 | -1 | 0.48 | |||||
Diluted Weighted Average Shares Outstanding | 466M | 466M | 466M | 466M | 466M | |||||
Normalized Basic EPS | 0.99 | 1.53 | 1.81 | 0.53 | 0.87 | |||||
Normalized Diluted EPS | 0.99 | 1.53 | 1.81 | 0.53 | 0.87 | |||||
Dividend Per Share | 1.15 | 1.17 | 1.17 | 1.17 | 1.17 | |||||
Payout Ratio | 115.27 | 71.85 | 100.93 | -117.2 | 245.5 | |||||
Supplemental Items | ||||||||||
EBITDA | 1.75B | 2.15B | 2.37B | 1.79B | 1.7B | |||||
EBITA | 1.04B | 1.43B | 1.57B | 756M | 971M | |||||
EBIT | 895M | 1.27B | 1.41B | 606M | 834M | |||||
EBITDAR | 1.76B | 2.16B | 2.38B | 1.8B | 1.7B | |||||
Effective Tax Rate - (Ratio) | 26.46 | 29.12 | 39.98 | -28.77 | 44.7 | |||||
Total Current Taxes | 244M | 337M | 325M | 92M | 199M | |||||
Total Deferred Taxes | -63M | -21M | 44M | 9M | -5M | |||||
Normalized Net Income | 460M | 715M | 844M | 248M | 404M | |||||
Interest Capitalized | 6M | 9M | 10M | 7M | 10M | |||||
Interest on Long-Term Debt | 16M | 23M | 27M | 38M | 41M | |||||
Non-Cash Pension Expense | 257M | 270M | 243M | 93M | 103M | |||||
Supplemental Operating Expense Items | ||||||||||
Selling and Marketing Expenses | 1.5B | 1.71B | 2.04B | 1.83B | 1.88B | |||||
General and Administrative Expenses | 502M | 539M | 530M | 489M | 740M | |||||
Research And Development Expense From Footnotes | 433M | 466M | 462M | 445M | 461M | |||||
Net Rental Expense, Total | 8M | 13M | 14M | 8M | 5M | |||||
Imputed Operating Lease Interest Expense | 2.68M | 3.73M | 3.66M | 3.79M | 2.21M | |||||
Imputed Operating Lease Depreciation | 5.32M | 9.27M | 10.34M | 4.21M | 2.79M | |||||
Stock-Based Comp., Other (Total) | -1.8M | 891K | 14.5M | 10.3M | 11.4M | |||||
Total Stock-Based Compensation | -1.8M | 891K | 14.5M | 10.3M | 11.4M |
- Stock Market
- Equities
- EVK Stock
- Financials Evonik Industries AG
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















